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Identification of Drug Metabolites of Tricyclic Antidepressant
Medications in Rat Liver Microsome Using Compact Mass
Spectrometry

Kathryn M. Senchea, Maya R. Fernando, Blessing I. Ojo, Dani K. Schmaus, and Dr. Myoung E. Lee
Department of Chemistry, Winona State University, Winona, Minnesota
ABSTRACT

DISCUSSION

CONCLUSION

MATERIALS AND METHODS

Prescription antidepressants are commonly used drugs to treat
depression and many other disorders. It is known that enzymes
metabolize most prescription drugs within the liver by altering
them to become more polar to allow for easy excretion through
the urine or bile. This study was done to determine the outcome
of metabolism of six different tricyclic antidepressants (TCA’s):
clomipramine, duloxetine, escitalopram, imipramine,
nortriptyline, and venlafaxine. These six drugs were mixed with
rat liver microsomes and an NADPH-generating system in a
phosphate buffer at pH 7.4. All samples were incubated for two
hours at 37°C. Each sample was subjected to the compact mass
spectrometer fitted with a C18 reverse phase column.
Duloxetine, escitalopram, and venlafaxine all underwent Ndemethylation but not aromatic hydroxylation during
metabolism. On the other hand, clomipramine, imipramine, and
nortriptyline failed to show N-demethylation nor aromatic
hydroxylation. Several controls were incubated and analyzed,
such as the mixture without the drug, the mixture without the
NADPH-generating system, the mixture without the rat liver
microsome, and a mixture of just the drug and buffer. The future
goal is to repeat these experiments using HPLC/CMS to separate
the metabolites further.

Venlafaxine, escitalopram, duloxetine, clomipramine, imipramine,
nortriptyline NADP, Glucose-6-Phosphate, Glucose-6-Phosphate
Dehydrogenase and rat liver microsome were purchased from Sigma
Aldrich. Luna C18 reverse phase column (3 micrometer, 50 mm x 2
mm) was purchased from Phenomenex. Each drug’s samples were
metabolized and evaluated using an Advion Expression S Compact
Mass Spectrometer equipped with an electrospray ionizer (ESI) and a
Phenomenex Luna C18 column. The running time was 15 minutes per
sample with a mobile phase of 95:5 acetonitrile:water and 2 mM
ammonium acetate with a 0.2 mL/min flow rate. The injection volume
was 5 𝜇L. Three different concentrations of each drug were used along
with four different controls. The drug concentrations were 100, 250,
and 800 𝜇𝑀. For each drug, 65 𝜇L of these concentrations along with a
mixture of 35 µL NADPH-generating system and 25 𝜇L microsomal
suspension in 50 mM potassium phosphate buffer at pH 7.4 were
added. The final concentration of NADP, glucose-6-phosphate, glucose6-phosphate dehydrogenase, and microsome were 1 mM, 5 mM, 0.5 U,
and 0.2 mg/mL, respectively. The four controls had the following
composition: (1) drug only, (2) drug with the microsome but without
NADPH-generating system, (3) drug with NADPH-generating system
only, and (4) NADPH-generating system and microsome without the
drug. Samples were then incubated at 37oC for a period of 2 hours and
then 250 𝜇L methanol was added to stop the reaction. These samples
were then centrifuged so that the supernatant could be taken and
diluted to 1/20 (venlafaxine and escitalopram) or 1/100 (duloxetine) in
the mobile phase before injecting the samples within the mass
spectrometer. All injections within the mass spectrometer were
performed in triplicates to ensure equal conditions for data
collection and calculations.

Escitalopram, duloxetine, and venlafaxine all underwent Ndemethylation but not aromatic hydroxylation during
metabolism in rat liver microsomes in vitro. Even though
duloxetine was just N-demethylated, it metabolized the most
of the three medications, up to 72.4%. Consequently, it was
established that rat liver microsomes were required for the
metabolism of escitalopram, venlafaxine, and duloxetine.
However, only escitalopram and venlafaxine were shown to
require an NADPH-generating system to produce metabolized
products. The other three tricyclic antidepressants,
nortriptyline, clomipramine, and imipramine were tested
using the same protocol. According to the findings, no
metabolites with hydroxylation or N-demethylation were
found in clomipramine, imipramine, or nortriptyline.

RESULTS
Venlafaxine

Escitalopram

Duloxetine

INTRODUCTION
Depression is a worldwide problem faced by
millions. Luckily, there are ways to manage
depression along with other disorders with the
use of antidepressants. Clomipramine,
escitalopram, duloxetine, imipramine,
nortriptyline, and venlafaxine are all known as
cyclic or tricyclic antidepressants (TCA’s). It is
known that Cytochrome P450 (CYP) enzymes
metabolize most prescription drugs within the
liver, and It is these same enzymes that
metabolize antidepressant medications.
CYP1A2, CYP2C19, and CYP2D6 are three of the
multiple enzymes used within the liver that
metabolize TCA’s. We propose investigating how
rat liver microsomes, which contain many CYP
enzymes, metabolize each of the six
medications through quantification and
interpretation of compact mass spectrometry
data.

Duloxetine
MW: 297.4
LogP : 4.72-5.00

Escitalopram
MW: 324.4
LogP: 3.78-4.74

Figure 1: CMS Chrom atogram of N-Dem ethylation
of Duloxetine
This figure shows three trials with their retention
time and area at the molecular weight of 284.2 with
the concentration of 800 𝜇𝑀. This is the molecular
weight of protonated duloxetine (298.2) with a
methyl group subtracted from it (-14).

Drug metabolites observed

N-desmethylescitalopram

Im ipram ine
MW: 280.4
LogP: 3.63-4.53

Figure 3: CMS Chrom atogram of N-Dem ethylation
and O-Dem ethylation of Venlafaxine

This figure shows three trials with their retention
time and area at the molecular weight of 311.2 with
the concentration of 800 𝜇𝑀. This is the molecular
weight of protonated escitalopram (325.4) with a
methyl group subtracted from it (-14).

Two defining peaks with a molecular weight of of 264.4 are
present. The molecular weight of protonated venlafaxine
(278.4) with a methyl group subtracted (-14) presents a
molecular weight of 264. 4. The peak with the lowest
retention is assumed to be O-demethylated venlafaxine
while the peak with the higher retention time is likely Ndesmethylvenlafaxine.
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Figure 2: CMS Chrom atogram of NDem ethylation of Escitalopram

Escitalopram was measured first. Seven samples were each injected in
triplicate. Three were of different drug concentrations (100, 250, and 800
μM), and four were controls. All samples measured through the compact
mass spectrometer (CMS) were subjected to ESI leading to protonation of
each drug and metabolite for the addition of +1 to the molecular weight.
The unmetabolized drug (325.2), the N-demethylated metabolite (311.2),
and the hydroxylated metabolite (343.2) were analyzed—the Ndemethylation of Escitalopram at 800 μM metabolized at an average of
0.75%. At the weight of 343.2, three weak peaks showed up in the 800 μM
sample, but later than the drug peaks, indicating that these peaks are
arising from something other than the metabolite. For the 100 μM and 250
μM concentrations, no peaks were seen at 343.2, further suggesting that
no hydroxylation occurred.
Venlafaxine was measured with the same seven samples in triplicate. The
unmetabolized drug (278.4), the N-demethylated metabolite (264.4), and
the O-demethylated metabolite (264.4) were analyzed. Since the two
demethylated metabolites have the same molecular weight, they were
distinguished based on their retention times and relative polarities. Using
relative LogP values, the O-demethylated metabolite was found to be
more polar than the drug itself and will elute first. The N-demethylated
metabolite was found to be more non-polar and will elute last. At the
weight of 264.4, two peaks were observed for each drug concentration.
One had a retention time earlier than the original drug peak, and the other
at a retention times later than the drug peak, indicating that both O and Ndemethylation occurred. At 800 μM, venlafaxine metabolized at an average
rate of 0.5% for the O-desmethyl metabolite and 1.4% for the N-desmethyl
metabolite.
Duloxetine was also injected into the CMS, measuring the same seven
samples in triplicate. A metabolite that underwent N-demethylation was
seen at a weight of 284.2 with strong peaks at each drug concentration.
This N-demethylation metabolized at an average of 72.4%. No peaks were
seen at the weight of 316.2, indicating that no hydroxylation occurred. Out
of the drugs measured, duloxetine metabolized the most, although the
reason for this is unclear. One possibility may be that duloxetine only has
one methyl group attached to the nitrogen while escitalopram and
venlafaxine have two. Another interesting finding was that metabolites
were seen in the sample containing only drug and microsome, but not the
NADPH-regenerating system, although this was not seen with any of the
other drugs. This indicates that duloxetine does not require the NADPHregenerating system to metabolize, while the other drugs do.
Finally, nortriptyline, clomipramine, and imipramine were also run through
the compact mass spectrometer. However, the results indicated that none
of these drugs showed N-demethylation nor aromatic hydroxylation. More
testing will need to be done in the future to determine if there were
errors in this experiment or to discover if tricyclic antidepressants can be
metabolized in other ways.
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